Login to Your Account

As AAN abstracts drop, attention flies to Bluebird’s CCALD data

By Marie Powers
News Editor

Friday, March 4, 2016

Abstracts from the 2016 annual meeting of the American Academy of Neurology drew swift reaction from analysts, who zeroed in on prospects for success in Bluebird Bio Inc.’s ongoing phase II STARBEAM trial of Lenti-D in childhood cerebral adrenoleukodystrophy, an ultra-rare and ultimately fatal disorder. 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription